GlaxoSmithKline data of Cervarix shows 100% efficacy

By Elaine Rigoli

Tampa, Fla., April 5 - Cervarix, GlaxoSmithKline's candidate vaccine for cervical cancer prevention, showed 100% efficacy over 4.5 years against precancerous lesions associated with human papillomavirus (HPV) types 16 and 18, the two most common cancer-causing HPV types, a new follow-up study shows.

Cervarix is formulated with the proprietary innovative adjuvant system AS04, selected to ensure this vaccine confers strong and sustained antibody levels in women, according to a news release.

The study, published in The Lancet, also found that HPV 16 and 18 antibodies were detected in over 98% of women for up to 4.5 years, indicating a sustained vaccine response, the release said.

In addition, the study provided evidence that Cervarix demonstrated substantial protection against infection with the third and fourth most prevalent cancer-causing types of HPV, namely types 45 and 31. This protection also extends over 4.5 years.

The company said it is conducting further large studies to determine the potential mechanism and extent of the demonstrated broader oncogenic protection.

HPV types 16, 18, 45 and 31 are collectively responsible for 80% of cervical cancers globally, the release said.

GlaxoSmithKline is a London-based pharmaceutical and health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.